Gray platelet syndrome: Proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice

Blood

Volumn 124, Issue 24, 2014, Pages 3624-3635

  Guerrero, Jose A ^a,b   Bennett, Cavan ^a,b   Van Der Weyden, Louise ^c   McKinney, Harriet ^a,b   Chin, Melody ^a,b   Nurden, Paquita ^d   McIntyre, Zoe ^c   Cambridge, Emma L ^c   Estabel, Jeanne ^c   Wardle Jones, Hannah ^c   Speak, Anneliese O ^c   Erber, Wendy N ^e   Rendon, Augusto ^a,b   Ouwehand, Willem H ^a,b,c   Ghevaert, Cedric ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d Ctr Geriatrie Ctr Hosp Univ B   (France)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NBEAL2 PROTEIN; PADGEM PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; NBEAL2 PROTEIN, MOUSE; PLASMA PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CELL GRANULE; CELL LOSS; CELL MATURATION; CONTROLLED STUDY; DISEASE COURSE; GENE; GRAY PLATELET SYNDROME; HEMOSTASIS; MEGAKARYOCYTE; METASTASIS; MOUSE; MURINE MODEL; MYELOFIBROSIS; NBEAL2 GENE; NONHUMAN; PHENOTYPE; PLATELET ALPHA GRANULE; PROTEIN DEPLETION; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTATION; MYELOID METAPLASIA; NEOPLASM; PATHOLOGY; SECRETORY VESICLE;

ANIMALS; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; GRAY PLATELET SYNDROME; HUMANS; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; PRIMARY MYELOFIBROSIS; SECRETORY VESICLES;

EID: 84915754336     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-566760     Document Type: Article

References (48)

1. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264-274.
2. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA. 2006;103(4):855-860.
3. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532-3548.
4. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423-1436.
5. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327(5965):580-583.
6. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-134.
7. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602-1612.
8. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096-2104.
9. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177-189.
10. Heijnen HF, Debili N, Vainchencker W, Breton-Gorius J, Geuze HJ, Sixma JJ. Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood. 1998;91(7):2313-2325.
11. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12):3348-3354.
12. Ambrosio AL, Boyle JA, Di Pietro SM. Mechanism of platelet dense granule biogenesis: study of cargo transport and function of Rab32 and Rab38 in a model system. Blood. 2012;120(19):4072-4081.
13. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med. 1971;51(6):818-828.
14. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
15. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-740.
16. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet. 2011;43(8):732-734.
17. Maynard DM, Heijnen HF, Gahl WA, Gunay-Aygun M. The α-granule proteome: novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost. 2010;8(8):1786-1796.
18. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21(1):21-36.
19. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14(3):307-311.
20. Castermans D, Volders K, Crepel A, et al. SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet. 2010;19(7):1368-1378.
21. Skarnes WC, Rosen B, West AP, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474(7351):337-342.
22. White JK, Gerdin AK, Karp NA, et al; Sanger Institute Mouse Genetics Project. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell. 2013;154(2):452-464.
23. Ryder E, Gleeson D, Sethi D, et al; Sanger Mouse Genetics Project. Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. Mamm Genome. 2013;24(7-8):286-294.
24. Hobbs CM, Manning H, Bennett C, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122(23):3787-3797.
25. Guerrero JA, Kyei M, Russell S, et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood. 2009;114(27):5541-5546.
26. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
27. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost. 2007;5(10):2009-2016.
28. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
29. Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24(2):133-145.
30. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165-178.
31. Deppermann C, Cherpokova D, Nurden P, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice [published online ahead of print July 1, 2013]. J Clin Invest.
32. Kahr WH, Lo RW, Li L, et al. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood. 2013;122(19):3349-3358.
33. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011;25(2):218-225.
34. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96(4):1342-1347.
35. White JG. Ultrastructural studies of the gray platelet syndrome. Am J Pathol. 1979;95(2):445-462.
36. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol. 1981;102(1):10-19.
37. Falik-Zaccai TC, Anikster Y, Rivera CE, et al. A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics. Mol Genet Metab. 2001;74(3):303-313.
38. Cramer EM, Vainchenker W, Vinci G, Guichard J, Breton-Gorius J. Gray platelet syndrome: immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes. Blood. 1985;66(6):1309-1316.
39. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362-2367.
40. Cooney CA, Jousheghany F, Yao-Borengasser A, et al. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011;13(3):R58.
41. Garcia J, Callewaert N, Borsig L. P-selectin mediates metastatic progression through binding to sulfatides on tumor cells. Glycobiology. 2007;17(2):185-196.
42. Monzavi-Karbassi B, Stanley JS, Hennings L, et al. Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer. 2007;120(6):1179-1191.
43. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001;98(6):3352-3357.
44. Köhler S, Ullrich S, Richter U, Schumacher U. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer. 2010;102(3):602-609.
45. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA. 2002;99(4):2193-2198.
46. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA. 1998;95(16):9325-9330.
47. Avanzi MP, Mitchell WB. Ex vivo production of platelets from stem cells. Br J Haematol. 2014;165(2):237-247.
48. Italiano JE Jr, Battinelli EM. Selective sorting of alpha-granule proteins. J Thromb Haemost. 2009;7(Suppl 1):173-176.